MedPath

Diaphragmatic Ultrasound to Predict the Therapeutic Effect of High-flow Nasal Cannula Oxygen Therapy

Not yet recruiting
Conditions
Hypoxic Respiratory Failure
Registration Number
NCT06336265
Lead Sponsor
Xingui Dai
Brief Summary

Follow-up was conducted for every patient requiring high-flow nasal cannula oxygen therapy in district 1 of the Intensive Care Department of Chenzhou NO.1 People's Hospital. Patients who met the inclusion criteria but did not meet the exclusion criteria were included for observation. Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment. Throughout the procedure, a panel of experts assessed whether the patient needed endotracheal intubation; If yes, the study was terminated; if no, high-flow nasal cannula oxygen therapy was continued, and observation and evaluation were continued until the end point of the study (12 hours after treatment). If patients or their family members do not want to continue to participate in the study during the study, they will be considered as withdrawal. If patients suffer from sudden malignant arrhythmia or cardiac arrest during the study, resulting in death or transfer to other hospitals or other departments during the study, patients will be excluded. Data from dropped and excluded patients were not included in the final statistical analysis. After the data of 269 patients were collected, the study was concluded, and the results and conclusions were derived by statistical analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
269
Inclusion Criteria
  1. Age ≥18 years old, less than 75 years old,BMI≥18.5kg/m2
  2. Mild to moderate type I respiratory failure (100mmHg< PaO2/FiO2≤300mmHg)
  3. Mild ventilation dysfunction (pH≥7.3)
  4. Mild respiratory distress (respiratory rate > 24 times/min)
  5. High-flow nasal cannula oxygen therapy is required
  6. The patient and immediate family members agree and sign a written informed consent.
Exclusion Criteria
  1. Patients with severe type II respiratory failure, severe asthma and massive hemoptysis
  2. Moderate to severe consciousness disorder, GCS score ≤12 points
  3. Cardiogenic pulmonary edema and cardiogenic dyspnea caused by heart failure, heart valvular disease, myocarditis, etc
  4. Hemodynamic instability, SBP< 90mmHg, or MAP<65mmHg
  5. BMI < 18.5kg/m2
  6. Nasal bleeding, nasal space occupying lesions, etc., can not be high-flow nasal cannula oxygen therapy through the nose or nasal obstruction
  7. Patients with severe hypoxemia, severe ARDS and other conditions requiring immediate tracheal intubation
  8. The patient or family member refuses to participate or does not agree to sign the written informed consent
  9. The patient has participated in other research projects with interventions

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Respiratory rate0-12 hours

Respiratory rate of the patient after high-flow nasal oxygen therapy

Diaphragmatic excursion0-12 hours

Diaphragmatic excursion was measured using a low-frequency curved array (" abdomen ") probe located directly below the costal arch on the midline of the clavicle.

Thickness and thickening fraction of Diaphragm0-12 hours

Diaphragm thickness and thickening fraction (TFdi) were measured using a high-frequency linear array probe at the midaxillary line. TFdi = (diaphragm thickness at the end of inspirations - diaphragm thickness at the end of expirations)/diaphragm thickness at the end of expirations × 100%

Incidence of tracheal intubation0-12 hours

After the patient uses high-flow nasal oxygen therapy, the panel determine whether the patient needs to undergo tracheal intubation according to the indicators such as symptoms and signs of the patient.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath